Inactivation of the antidiabetic drug acarbose by human intestinal microbial-mediated degradation

Abstract

Abstract Gut microbiota plays an important role in drug modification, transformation and degradation, which are factors that need to be considered in personalized therapy. Acarbose, an inhibitor of α-glucosidase, is used as a first-line drug for the treatment of type 2 diabetes; however, its clinical effects vary greatly among individuals, and the underlying mechanisms relating to the contribution of gut microbes remain to be elucidated. Herein, we reported the association between acarbose resistance and enteric bacteria by analyzing clinical samples and anaerobic enrichment culture, and isolated a major acarbose-degrading gut strain, Klebsiella grimontii TD1. Metagenomic analysis of the intestinal microbiome found that the abundance of K. grimontii TD1 was higher in patients with weak acarbose response and increased with longer medication time. In addition, in vivo experiments using a diabetic mouse model showed that this strain significantly weakened the hypoglycemic effect of acarbose. Further, we identified a key acarbose-preferred glucosidase, Apg, in K. grimontiiTD1 using a combined approach of induced transcriptome and protein profiling. This enzyme is structurally characteristic, could degrade acarbose into small molecules with loss of inhibitor function, and was widely distributed in intestinal microorganisms, especially in Klebsiella. These results indicate that the risk of acarbose resistance caused by metabolic degradation from intestinal bacteria is widespread in humans, and this "induced degradational inactivation" mechanism may be one of the main causes of non-antibiotic drug resistance.